The 12-month prevalence and nature of adverse experiences resulting in emergency medical presentations associated with the use of synthetic cannabinoid products

Human Psychopharmacology

Volumn 28, Issue 4, 2013, Pages 390-393

  Winstock, Adam R ^a,b   Barratt, Monica J ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Global Drug Survey   (United Kingdom)

^c CURTIN UNIVERSITY   (Australia)

Author keywords

cannabis; emergency; herbal incense; legal highs; synthetic cannabinoids; toxicity

Indexed keywords

CANNABINOID;

ADULT; ADVERSE OUTCOME; AGGRESSION; AGITATION; ANXIETY; AUDITORY HALLUCINATION; BREATHING DISORDER; CLINICAL FEATURE; CONFERENCE PAPER; EMERGENCY CARE; EMERGENCY WARD; FEMALE; HEALTH SURVEY; HUMAN; INTOXICATION; MAJOR CLINICAL STUDY; MALE; PANIC; PARANOIA; PREVALENCE; PRIORITY JOURNAL; SELF CONCEPT; SUBSTANCE ABUSE; THORAX PAIN; VISUAL HALLUCINATION;

CANNABIS; EMERGENCY; HERBAL INCENSE; LEGAL HIGHS; SYNTHETIC CANNABINOIDS; TOXICITY;

ADOLESCENT; ADULT; CANNABINOIDS; DATA COLLECTION; EMERGENCY MEDICAL SERVICES; FEMALE; HUMANS; MALE; MARIJUANA SMOKING; PREVALENCE; YOUNG ADULT;

EID: 84880778742     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2292     Document Type: Conference Paper

References (35)

1. Barratt MJ, Cakic V, Lenton S,. In press. Patterns of synthetic cannabinoid use in Australia. Drug Alc Rev. DOI: 10.1111/j.1465-3362.2012.00519. x.
2. Castellanos D, Thornton G,. 2012. Synthetic cannabinoid use: recognition and management. J Psychiatr Pract 18: 86-93.
3. Crippa JA, Zuardi AW, Martín-Santos R, et al,. 2009. Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol 24: 515-523.
4. Cohen J, Morrison S, Greenberg J, et al,. 2012. Clinical presentation of intoxication due to synthetic cannabinoids. Pediatrics 129: e1064-e1067.
5. de Havenon A, Chin B, Thomas KC, et al,. 2011. The secret "spice": an undetectable toxic cause of seizure. The Neurohospitalist 1: 182-186.
6. Degenhardt L, Hall W, Lynskey M,. 2003. Exploring the association between cannabis use and depression. Addiction 98: 1493-1504.
7. European Monitoring Centre for Drugs and Drug Addiction. 2010. 2010 Annual report on the state of the drugs problem in Europe. EMCDDA, Luxembourg.
8. Every-Palmer S,. 2011. Synthetic cannabinoid JWH-018 and psychosis: an explorative study. Drug Alcohol Depend 117: 152-157.
9. Fattore L, Fratta W,. 2011. Beyond THC: the new generation of cannabinoid designer drugs. Front Behav Neurosci 5: Article 60.
10. Forrester MB, Kleinschmidt K, Schwarz E, et al,. 2011. Synthetic cannabinoid exposures reported to Texas Poison Centers. J Addict Dis 30: 351-358.
11. Hoyte CO, Jacob J, Monte AA, et al,. 2012. A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010. Ann Emerg Med 60: 435-438.
12. Hudson S, Ramsey J,. 2011. The emergence and analysis of synthetic cannabinoids. Drug Test Anal 3: 466-478.
13. Hurst D, Loeffler G, McLay R,. 2011. Psychosis associated with synthetic cannabinoid agonists: a case series. Am J Psychiatry 168: 1119.
14. McCambridge J, Hunt N, Winstock A, et al,. 2005a. Has there been a decline in the prevalence of cannabis use among British nightclubbers Five-year survey data. Drugs Educ Prev Pol 12: 167-169.
15. McCambridge J, Mitcheson L, Winstock A, et al,. 2005b. Five-year trends in patterns of drug use among people who use stimulants in dance contexts in the United Kingdom. Addiction 100: 1140-1149.
16. Miller PG, Sønderlund AL,. 2010. Using the internet to research hidden populations of illicit drug users: a review. Addiction 105: 1557-1567.
17. Mir A, Obafemi A, Young A, et al,. 2011. Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics 128: e1622-e1627.
18. Schep LJ, Slaughter RJ, Temple WA, et al,. 2011. Synthetic cannabinoid analogues-not repeating past mistakes. N Z Med J 124: 85-86.
19. Schneir AB, Baumbacher T,. 2012. Convulsions associated with the use of a synthetic cannabinoid product. J Med Toxicol 8: 62-64.
20. Smith DE,. 1968. Acute and chronic toxicity of marijuana. J Psychedelic Drugs 2: 37-47.
21. Thomas H.,. 1993. Psychiatric symptoms in cannabis users. Br J Psychiatry 163: 141-149.
22. Tien AY, Anthony JC,. 1990. Epidemiological analysis of alcohol and drug use as risk factors for psychotic experiences. J Nerv Ment Dis 178: 473-480.
23. van Os J, Bak M, Hanssen M, et al,. 2002. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 156: 319-327.
24. Vandrey R, Dunn KE, Fry JA, et al,. 2012. A survey study to characterize use of Spice products (synthetic cannabinoids). Drug Alcohol Depend 120: 238-241.
25. Vardakou I, Pistos C, Spiliopoulou C,. 2010. Spice drugs as a new trend: mode of action, identification and legislation. Toxicol Lett 197: 157-162.
26. Warhaft G.,. 2011. Not for human consumption The banning of synthetic cannabinoids. Of Substance 9: 14-17.
27. Wells DL, Ott CA,. 2011. The "new" marijuana. Ann Pharmacother 45: 414-417.
28. Weil AT,. 1970. Adverse reactions to marihuana. N Engl J Med 282: 997-1000.
29. Winstock AR, Barratt MJ,. In press. Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug Alcohol Depend DOI: 10.1016/j.drugalcdep.2012.12.011.
30. Winstock AR, Griffiths P, Stewart D,. 2001. Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug Alcohol Depend 64: 9-17.
31. Winstock AR, Mitcheson LR, Deluca P, et al,. 2011a. Mephedrone, new kid for the chop? Addiction 106: 154-161.
32. Winstock AR, Mitcheson L, Gillatt DA, et al,. 2012. The prevalence and natural history of urinary symptoms among recreational ketamine users. BJU Int 110: 1762-1766.
33. Winstock A, Mitcheson L, Ramsey J, et al,. 2011b. Mephedrone: use, subjective effects and health risks. Addiction 106: 1991-1996.
34. Winstock AR, Wolff K, Ramsey J,. 2002. 4-MTA: a new synthetic drug on the dance scene. Drug Alcohol Depend 67: 111-115.
35. Zammit S, Moore TH, Lingford-Hughes A, et al,. 2008. Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br J Psychiatry 193: 357-363.